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Retinitis pigmentosa (RP) is a genetic disease causing progressive
apoptotic death of photoreceptors and, ultimately, incurable blind-
ness. Using the retinal degeneration 10 (rd10) mouse model of RP,
we investigated the role of ceramide, a proapoptotic sphingolipid,
in retinal degeneration. We also tested the possibility that photo-
receptor loss can be slowed or blocked by interfering with the
ceramide signaling pathway of apoptosis in vivo. Retinal ceramide
levels increased in rd10 mice during the period of maximum
photoreceptor death. Single intraocular injections of myriocin,
a powerful inhibitor of serine palmitoyl-CoA transferase, the rate-
limiting enzymeof ceramide biosynthesis, lowered retinal ceramide
levels to normal values and rescued photoreceptors from apoptotic
death. Noninvasive treatment was achieved using eye drops
consisting of a suspension of solid lipid nanoparticles loaded with
myriocin. Short-term noninvasive treatment lowered retinal ceram-
ide in a manner similar to intraocular injections, indicating that
nanoparticles functioned as a vector permitting transcorneal drug
administration. Prolonged treatment (10–20d)with solid lipidnano-
particles increased photoreceptor survival, preserved photorecep-
tormorphology, andextended theabilityof the retina to respond to
light as assessed by electroretinography. In conclusion, pharmaco-
logical targeting of ceramide biosynthesis slowed the progression
of RP in a mouse model, and therefore may represent a therapeutic
approach to treating this disease in humans. Transcorneal adminis-
tration of drugs carried in solid lipid nanoparticles, as experimented
in this study, may facilitate continuous, noninvasive treatment of
patients with RP and other retinal pathologies.
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Retinitis pigmentosa (RP), one of the leading causes of blind-ness worldwide, comprises numerous retinal dystrophies of
genetic origin frequently caused by mutations in genes essential
to rod photoreceptor function and metabolism, resulting in rod
cell death and subsequent night blindness (1). Progressively, cone
photoreceptors also die, until all useful sight is lost. Although
there is presently no cure for RP, substantial progress has been
made to elucidate the genetics and cell biology of these disorders.
In particular, rod photoreceptor death in RP is largely thought
to occur by apoptosis (2–5), although nonapoptotic mechanisms
have also been proposed (5).
Among known proapoptotic cellular messengers, the sphin-
golipid ceramide is a well-characterized death effector in various
experimental models and pathological conditions (6–9). Endog-
enous cellular levels of ceramide increase after stimulation with
different proapoptotic factors that cause acute and chronic dis-
ease (10, 11). This increase in ceramide can originate from an
activation of de novo biosynthesis, a rise in ceramide hydrolysis
from sphingomyelin by the action of neutral or acid sphingo-
myelinases, or a decrease in ceramide metabolism due to gly-
cosylation, phosphorylation, or deacetylation (12). An important
role for ceramide-mediated apoptosis in neurodegenerative and
neuroinﬂammatory diseases has now been established (10).
Several lines of evidence suggest that ceramide also mediates
apoptosis in retinal photoreceptors (13). First, in Drosophila
models of RP, genetic manipulation of sphingolipid metabolism
has protective effects on retinal morphology and function; pro-
tection was achieved both by expressing neutral ceramidase in
Drosophila eye, to reduce cellular levels of ceramide, and by
knocking out one copy of a gene encoding a subunit of serine
palmitoyl-CoA transferase (SPT), the enzyme that controls the
rate-limiting step of ceramide biosynthesis (14). In humans, a di-
rect genetic link between retinal degeneration and sphingolipid-
mediated apoptosis has been established with the discovery that
a loss-of-function mutation in CERKL, a gene expressing ceram-
ide kinase-like protein, caused autosomal recessive RP (15, 16),
although debate exists on the pathway leading to cell death in
individuals with this mutation (17). In rat retinal neuronal primary
cultures, oxidative stress increased ceramide levels and caused
apoptosis, whereas these effects were blocked by addition of
docosahexaenoic acid to stimulate antiapoptotic responses (18).
Similarly, in the murine 661W photoreceptor cell line, oxidative
stress stimulated acid sphingomyelinase and increased ceramide
levels, thereby activating themitochondrial apoptotic pathway and
the caspase cascade (19). Finally, in a rabbit model of retinal ap-
optosis, ceramide increased after experimental retinal detachment
(20). Altogether, these studies document that the accumulation of
ceramide is associated with retinal degeneration and suggest that
pharmacological interventions altering sphingolipid metabolism
may have therapeutic potential.
Effective RP therapies might be implemented on biological
models that accurately represent retinal degeneration in humans.
Recently, the retinal degeneration 10 (rd10) mouse, with a mis-
sense mutation in the β-subunit of the rod-speciﬁc phosphodi-
esterase gene (21), has been shown, through morphological and
functional retinal analyses, to be a faithful model of typical hu-
man RP (22, 23). In this mutant, photoreceptors begin to die
from apoptosis during the third week of life, after the postnatal
period of retinal maturation, and photoreceptor death peaks
around postnatal day 24 (P24) (22, 23). As in typical human RP,
rods die ﬁrst, whereas cones are lost subsequently. Morpholog-
ically, the loss of photoreceptors is accompanied by a progressive
thinning of the outer retina and consequent reduction in the
number of photoreceptor rows from 12 to 14 on P10 to only 2–3
rows on P30. Functionally, rod-mediated retinal responses to
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light are measurable by electroretinography (ERG) from P14
(the day of eye opening) until P28, although the responses are
slow and weak compared with those of wild-type mice (23).
The availability of the rd10 mouse model of RP permitted us
to investigate whether pharmacological treatment with myriocin,
a selective inhibitor of SPT, could reduce ceramide and thereby
exert a protective effect against retinal degeneration. Myriocin,
a fungal metabolite discovered for its immunosuppressant
properties, is an atypical amino acid with a long hydrophobic tail,
structurally similar to sphingosine (24). To our knowledge,
myriocin has never been tested for protective effects on retinal
degeneration. Here we show that retinas of rd10 mice pups have
unusually high levels of ceramide which can be reduced by top-
ical administration of myriocin, concomitantly obtaining both
protection of photoreceptors from apoptotic death and mainte-
nance of ERG functional response. Furthermore, we show that
noninvasive drug delivery can be achieved using eye drops con-
taining a suspension of myriocin-loaded solid lipid nanoparticles.
Results
To determine whether, in the rd10 mouse model of RP, there are
altered levels of retinal ceramide, retinas were obtained between
P12 and P30 from rd10 mice pups and from wild-type animals of
the same genetic background. Total retinal ceramide, normal-
ized to the amount of inorganic phosphate (Pi) from total
phospholipid, was similar in the two groups until P16, after which
ceramide content started to increase in rd10 animals but con-
tinued to slowly decrease in wild-type mice (Fig. 1A). Signiﬁcant
differences between wild-type and rd10 mice were observed at
P21 (P = 0.045, t test) and P30 (P = 0.001), that is, during the
period of maximum retinal degeneration in rd10 mice. To test
whether these pathologically high levels could be reduced
pharmacologically, we administered myriocin by intraocular in-
jection on P19 followed by ceramide quantiﬁcation on P21. In 14
of 16 mice, myriocin injection into the right vitreous body re-
duced retinal ceramide levels below that of the left eye, injected
with vehicle alone (Fig. 1B). Overall, myriocin induced a 25.4%
reduction in mean ceramide content, from 4.09 pmol/nmol Pi
(SD = 1.16) to 3.05 pmol/nmol Pi (SD = 0.97) (P = 0.011,
paired t test). This treatment was therefore effective in bringing
ceramide to levels considered normal for P21. Similar treatment
of wild-type mice also reduced ceramide content, by 17.5%, from
a mean of 2.00 pmol/nmol Pi (SD = 0.34) to 1.65 pmol/nmol Pi
(SD = 0.12) (P = 0.032, paired t test).
A possible protective effect of intraocular myriocin injection on
photoreceptor survival was investigated by assessing the relative
abundance of apoptotic photoreceptors in retinas from myriocin-
and DMSO-treated eyes. Isolated retinas were stained with
a ﬂuorescent nuclear dye to identify pycnotic (condensed) nuclei
and visualized with confocal microscopy. Retinas from myriocin-
treated right eyes had fewer intensely stained nuclei than vehicle-
treated left eyes (Fig. 2 A and B). Quantitative analysis revealed
that 2 d after a single myriocin injection, the number of pycnotic
photoreceptor nuclei was reduced by 52.6%(P=0.007, t test) (Fig.
2C). To determine whether these protective cellular effects were
associated with a maintenance of retinal function, we measured
electrical responses to light by ERG 2 d after a single injection of
drug or vehicle. ERG traces from myriocin-treated eyes over-
lapped with those from DMSO-treated eyes (Fig. S1). Thus, de-
spite a preservation of cellular viability, a single injection of
myriocin did not have measurable functional beneﬁts.
Recognizing that continual pharmacological treatment may be
necessary to achieve positive effects on retinal function, we
topically administered 0.5 nmol myriocin (1 μL of 3.77 mM so-
lution in DMSO) to the cornea of rd10 mice once daily for 4 d.
Microscopic analysis for pycnotic nuclei and ceramide quantiﬁ-
cation revealed no signiﬁcant difference between myriocin- and
DMSO-treated retinas, suggesting that the drug did not cross the
cornea. Therefore, we investigated the possibility of using solid
lipid nanoparticles (SLNs) as vehicle to carry the drug across
ocular tissues; SLNs are pure lipid particles with a diameter of
40–200 nm. First, we assessed the ability of ﬂuorescently labeled
SLNs to reach the interior of the mouse eye. SLNs labeled with
the hydrophobic dye N-(7-nitro-2-1,3-benzoxadiazol-4-yl)-1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine (NBD-DPPE) were
topically applied to the ocular surface of wild-type mice once
daily for 3 d. Confocal microscopy of vertical retinal slices re-
vealed the presence of bright aggregates inside the retina (absent
from eyes treated with unlabeled SLNs), mostly in the outer
nuclear layer (ONL) and also between the photoreceptors and
the retinal pigment epithelium (Fig. 3A). Spectral analysis con-
ﬁrmed that the observed aggregates contained the NBD-DPPE
ﬂuorophore (Fig. 3B). Similar observations were obtained for
SLNs labeled with coumarin and Nile red. These results dem-
onstrated the feasibility of using SLNs to deliver small, lipophilic
molecules across the cornea to the photoreceptors and to the
retinal pigment epithelium.
SLNs were subsequently prepared with myriocin. The concen-
tration of the drug in different preparations, considered suitable
for use in rd10 mice, ranged from 0.4 to 1.0 mM (mean, 0.6 mM).
Myriocin-SLNs were administered topically to both corneas of
rd10 mice, three times per day for 3 d starting on P19; additional
rd10 mice were treated with control SLNs. In retinas collected on
P21,mean values of ceramidewere 2.49 pmol/nmol Pi (SD=0.25)
in myriocin-treated animals but 4.19 pmol/nmol Pi (SD= 0.92) in
control animals (P < 0.001, t test). These results document that
myriocin can be effectively administered across the cornea when
incorporated into SLNs. However, despite the fact that this
treatment reduced retinal ceramide by 40.6% (even more than
with a single intraocular injection), still no signiﬁcant effect was
observed on retinal functional responses. Therefore, long-term
treatment with myriocin-SLNs was investigated.
Fig. 1. Ceramide content in mouse retina and effect of
myriocin. (A) Time course of endogenous ceramide con-
tent in retinas of mice pups during the ﬁrst month of life:
in rd10 mice, ceramide levels begin to increase during the
third week of life, in concomitance with retinal de-
generation. Values are mean and SE of three to ﬁve ret-
inas per data point. *P = 0.050; **P = 0.001, t test. (B)
Effect of intraocular myriocin injection on retinal ceram-
ide content in rd10 mice. Right eyes were injected on P19
with a single dose of myriocin; left eyes were treated with
vehicle. Ceramide content was assessed on P21. Animals
are shown in order of increasing ceramide content in
myriocin-treated retinas. In 14 of 16 animals, myriocin
lowered ceramide content; P = 0.030, paired t test.








Starting on P14, rd10 and wild-type (control) mice were treated
once daily with myriocin-SLNs or control SLNs. From P21 to P35,
different animals underwent ERG testing of retinal function fol-
lowed by retinal microscopic analysis. Myriocin treatment in wild-
type animals had no effect on ERG, which showed the typically
large amplitudes of a and b waves (Fig. S2). In both control and
myriocin-treated rd10 mice, mean amplitudes of ERG b waves
decreased progressively over time in concomitance with retinal
degeneration; similar results were observed for absolute values of
meanERGawaves (Fig. 4). However, absolute values of themean
amplitudes were larger inmyriocin-treated than control animals at
all time points except P35, when b-wave amplitudes were essen-
tially identical. Signiﬁcant differences between the two groups
were observed for a-wave amplitudes at P30 andP35. These results
indicate that continual topical application of myriocin-SLNs can
counteract, to a certain extent, the loss of function due to photo-
receptor death in rd10 mice.
The maximum effects of myriocin treatment on retinal re-
sponses to light of increasing intensity are illustrated in Fig. 5,
which shows ERG traces from two rd10mice pups treated for 10 d
(P14–P24) with either myriocin-SLNs or control SLNs. In the
myriocin-treated animal, there is higher preservation of both a and
b waves of the ERG.
To assess the morphological effects of treatment with myriocin-
SLNs on photoreceptors, we counted the number of photore-
ceptor rows in the outer nuclear layer, considered amore sensitive
measure of photoreceptor survival over long periods of treatment
than the number of pycnotic nuclei. Microscopic analysis of ver-
tical retinal sections revealed a protective effect of myriocin on
the number of photoreceptor rows, seen as a thicker cross-section
of the outer nuclear layer (Fig. 6A). This effect was signiﬁcant at
both P24 and P30 (Fig. 6B). The morphology of surviving pho-
toreceptors was preserved as well, as documented by the presence
of rhodopsin and cone opsin immunoreactivity in well-organized
outer segments of rods and cones, by retention of synaptic ter-
minals of these cells, and by the presence of well-organized den-
drites in rod bipolar cells (Fig. S3).
Finally, in a preliminary assessment of safety of long-term
treatment, eyes from anesthetized rd10 and wild-type mice
treated for 14 d with myriocin-SLNs were examined under
a dissection microscope before enucleation for signs of con-
junctiva irritation/edema, which were absent. Cataract and cor-
neal opacities could be excluded by the fact that we successfully
recorded ERGs. Nuclear staining of retinal sections with ethi-
dium revealed normal retinal histology. Immunohistochemical
analyses did not reveal macrophage inﬁltration (which would
have indicated inﬂammation) nor microglial activation (Fig. S4).
An extension of beneﬁcial effects of myriocin-SLN treatment
to retinal cones is anticipated by the morphological preservation
of these cells in myriocin-SLN-treated retinas, as well as the
recording of a larger cone-driven ERG in rd10 mice treated with
myriocin-SLNs for 26 d, compared with control animals (Figs.
S3B and S5).
Discussion
This study found that, in the rd10 mouse model of RP, the level
of retinal ceramide begins to increase from the third week of life,
during the period of maximum photoreceptor loss, whereas in
wild-type mice ceramide levels progressively decrease. Single
intraocular injections of myriocin, a selective inhibitor of SPT,
the rate-limiting enzyme of ceramide biosynthesis, decreased
Fig. 2. Intraocular myriocin injection slows
photoreceptor loss. (A and B) Fluorescence mi-
croscopy of retina whole mounts, ﬁxed and
stained with ethidium homodimer, from mice
treated with vehicle (A) or myriocin (B) on P19.
Myriocin injection was associated with a re-
duction in the number of pycnotic photore-
ceptor nuclei on P21. (C) Quantiﬁcation of
pycnotic nuclei per retina. Values are mean (SE)
of 16 mice. **P = 0.007, t test.
Fig. 3. Topically administered SLNs reach retinal photoreceptors. (A) Fluo-
rescence microscopy of a vertical section of wild-type mouse retina, 3 d after
repeated topical applicationof SLNs labeledwith thehydrophobicﬂuorescent
dye NBD-DPPE: bright puncta (arrows) are seen in the outer nuclear layer
(ONL) and between photoreceptors and the retinal pigment epithelium (RPE).
(Inset) High-magniﬁcation of ﬂuorescent puncta of different brightness. INL,
inner nuclear layer; IPL, inner plexiform layer. (B) Fluorescence emission
spectra from a smear of NBD-DPPE-labeled SLNs (Left) and from puncta in
retinal sections of treated mice (Right). The two spectra have the same shape
and peak emission at 520 nm, similar to that of NBD-DPPE (39).
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retinal ceramide and reduced the number of apoptotic photo-
receptors in the short term. A functional beneﬁt of myriocin was
observed after prolonged daily treatment, achieved by the non-
invasive, transcorneal administration of the drug contained in
solid lipid nanoparticles. In rd10 mice treated with myriocin-
SLNs for 10–20 d, the pathological decrease in photoreceptor
number was slowed, photoreceptor morphology was preserved,
and the degeneration of retinas was delayed.
The ﬁnding that ceramide levels increase in the rd10 mouse in
temporal association with the process of photoreceptor demise
(22, 23) provides biochemical evidence that this sphingolipid is
involved in the neurodegenerative pathology of RP. This result is
therefore in accordance with the knowledge derived from genetic
studies that human autosomal recessive RP can be caused by loss-
of-functionmutations inCERKL, an enzyme that lowers ceramide
content by phosphorylation (15). The results are also in agreement
with the increased ceramide levels found in tissues from individ-
uals with other pathologies leading to apoptosis, such as brain
tissue from Alzheimer’s disease patients (25), and thus provide
additional evidence that elevated ceramide is a pathogenetic fac-
tor of various diseases. Moreover, the fact that in vivo reduction of
retinal ceramide levels slowed disease progression extends to
mammals earlier results obtained inDrosophilamodels ofRP (14).
Therefore, these experiments provide a proof of principle that
ceramide regulation represents a relevant therapeutic target inRP
as in other pathologies (6, 12, 26–30). Compared with a previous
study in Drosophila models of RP (14), in which retinal ceramide
levels were lowered by genetic manipulation, in this study ceram-
ide levels were lowered pharmacologically. Because noninvasive
pharmacological intervention is more easily achieved in humans
than gene therapy, the strategy proposed here might become ap-
plicable to humans in the long run.
A functional beneﬁt of myriocin was observed only after
prolonged treatment but not after a single intraocular adminis-
tration, despite the fact that both administration methods re-
duced ceramide levels. The lack of measurable functional effects
of single myriocin administrations might be ascribed to the small
proportion of photoreceptors rescued from apoptotic death in
the short period of study (2 d). Possibly the corresponding effect
on the ERG fell below the sensitivity of this functional test.
This study has a few limitations, the most evident being that
chronic administration of myriocin rescued a fraction of photo-
receptors for a limited time, mostly delaying the inevitable death
process in these cells. However, it has to be considered that
prolonging the natural evolution of a disease like RP, which
characteristically exhibits a slow progression, can nonetheless be
beneﬁcial for patients. Another limitation is that we studied
a single genetic paradigm of RP, whereas it is known that this
disease is genetically heterogeneous. Different mutations leading
to photoreceptor demise could activate different pathways of
apoptosis (31), within which the sphingolipidic cascade could
play more or less relevant roles, which need to be studied.
Overall, the results described here are particularly encourag-
ing, considering that the partial loss-of-function rd10 mutation
mimics typical RP forms with moderately aggressive phenotype
and good retention of retinal architecture (23). These are fea-
tures that portray human RP patients as likely candidates for
gene therapy, in which the defective gene is replaced by a func-
tioning one by means of genetically engineered viral vectors (32).
A protective pharmacological approach, based on the non-
invasive administration of SPT inhibitors, could prolong the
lifespan of photoreceptors in recessive forms of RP, pending
gene therapy at a later stage. SPT inhibitors similar to myriocin
could therefore contribute to enlarge the panel of bioactive
substances already used as neuroprotectants to delay photore-
ceptor death in this disease (33, 34). In addition, considering that
an increment in the rate of rod survival is known to promote a
proportionally longer viability of cones, essential for daylight vi-
sion, it is possible that the beneﬁcial effects of delaying the
sphingolipid-mediated rod demise would propagate to cones as
well. Finally, the particular pharmacological strategy used here,
based on the employment of lipophilic, tissue-permeant drops,
represents a suitable method to deliver molecules to the inner eye
noninvasively. Various carriers (i.e., bio- and nonbiodegradable
implants, microspheres, nanoparticles, liposomes, and gels) have
been tested experimentally to deliver drugs to the inner eye (35).
The particular advantages of the SLNs used here are their lack of
undesirable effects and their suitability for carrying nonpolar, li-
pophilic compounds. These features can be exploited for drug
delivery in retinal disorders other than RP.
In conclusion, this study demonstrates that pharmacological
targeting of ceramide biosynthesis has the potential to slow the
progression of RP in a mammalian model and therefore may rep-
resent a therapeutic approach to treating this disease in humans.
Transcorneal administration of drugs carried in solid lipid nano-
particles, as experimented in this study, may also be developed for
human patients with other ocular disorders requiring therapy with
lipophilic molecules.
Methods
Animals. rd10 mice (Jackson Laboratories strain B6.CXB1-Pde6brd10/J) (36) and
wild-type mice (Jackson Laboratories strain C57BL/6J) were kept in a local
facility with water and food ad libitum in a 12-h light/dark cycle with illu-
mination level below 60 lux. Mice were handled according to Italian laws
and following the Association for Research in Vision and Ophthalmology
Fig. 4. Effects of long-term administration of myriocin-SLNs on retinal
physiology. (A) Amplitudes of ERG a and b waves from eyes of rd10 mice
treated with control SLNs or myriocin-SLNs from P14 and exposed to a light
ﬂash of 5.1 cd·s/m2. Values are mean and SE. Mice treated with myriocin-
SLNs (red bars) have larger mean a-wave amplitudes at P30 and P35 (*P =
0.050, Wilcoxon–Mann–Whitney test). (B) Representative ERG responses to
light from two rd10 mice treated for 10 d (from P14 to P24) with myriocin-
SLNs (red trace) or control SLNs (black trace). Note the preservation of the
a wave following myriocin treatment (arrow).








(ARVO) statement for the use of animals in research. Protocols were ap-
proved by the Italian Ministry of Veterinary Health.
Quantiﬁcation of Retinal Ceramide. Mice were anesthetized with an i.p. in-
jection of avertin (0.5 g/mL 2,2,2-tribromoethanol in ter-amylic alcohol; 20 μL/
g body weight). Eyes were quickly removed and retinas were detached,
placed in oxygenated artiﬁcial cerebral-spinal ﬂuid medium, and frozen on
dry ice. Retinal lipid was extracted using the Bligh–Dyer method, and total
phospholipid was quantiﬁed using the Ames method of Pi determination.
Ceramide was determined by diglyceride kinase assay (SI Methods).
Intraocular Injections. Mice were anesthetized as above. Using a dissecting
microscope, 500 nL of a 1.88 mM solution of myriocin in DMSO was injected
into the right vitreous body using a 10-μL glass Hamilton syringe driven by an
oil microinjector. Considering that the injected volume is diluted seven- to
eightfold within the vitreous body (37), this dosage provides an intraocular
concentration of ≈0.23 mM myriocin, one order of magnitude higher than
that used to inhibit SPT enzymatic activity in single-layer cell-culture studies
(38). An identical volume of DMSO vehicle was injected into the left eyes of
the same animals.
Fluorescence Microscopy of Retinas for Pycnotic Photoreceptors. Mice were
anesthetized as described earlier, and eyes were enucleated and ﬁxed with
4% paraformaldehyde in 0.1 M sodium phosphate (pH 7.2). Retinas were
detached and stained with 2 μM ethidium homodimer 2 (Invitrogen),
a ﬂuorescent DNA-intercalating molecule to which ﬁxed tissue is permeable.
Whole-mounted retinas were examined under a Leica TCS-SP confocal mi-
croscope for the presence of pycnotic (apoptotic) photoreceptor nuclei,
brighter than others in the same layer because of the high density of their
Fig. 5. Effects of myriocin-SLNs on ERG. The best examples of ERG responses to ﬂashes of light of increasing intensity from two rd10 mice age P24. Traces in
the panel corresponding to the lowest light intensity are purely rod-driven, whereas the others represent mixed rod–cone responses. Red traces, responses
from a mouse treated with myriocin-SLNs; black traces, responses from a mouse treated with control SLNs. In this instance, the SLNs contained the highest
myriocin concentration (1 mM) of this study.
Fig. 6. Effects ofmyriocin-SLNs on retinal morphology. (A and B) Vertical retinal sections from rd10mice treatedwith control SLNs (A) andmyriocin-SLNs (B) for
10d (fromP14 toP24). Theouter nuclear layer (ONL) of themyriocin-treated retina is thicker because it containsmorephotoreceptor rows than the control retina.
These micrographs are from the same animals whose ERG data are shown in Fig. 4B. INL, inner nuclear layer; OPL, outer plexiform layer. (C) Quantiﬁcation of
photoreceptor rows at P24 and P30 in rd10 mice treated with control SLNs or myriocin-SLNs. Data are mean and SE. *P = 0.002, **P = 0.003, t test.
18710 | www.pnas.org/cgi/doi/10.1073/pnas.1007644107 Strettoi et al.
condensed DNA. The ONL, containing the nuclei of photoreceptors, was
sampled along the whole z axis. Photoreceptor pycnotic nuclei were counted
on projection images of the ONL in ﬁelds of 150.6 × 150.6 μm2 (32 ﬁelds/retina),
spaced at 500-μm intervals along the dorsal-ventral and nasal-temporal
retinal meridians. The total number of pycnotic photoreceptors for each
retina was calculated by multiplying the average density of pycnotic cells in
ﬁeld images by the corresponding retinal area, measured by low-power light
microscopy with an image analyzer (Metamorph 5.0, Universal Imaging
Corporation).
Electroretinography. Retinal viability and function were assessed by recording
ﬂash electroretinograms as previously described (23); details are given in SI
Methods. When using mice treated with SLNs, ERG traces were recorded
simultaneously from both eyes, identically treated. The possible diffusion of
SLNs from one eye to the other made it necessary to use different mice for
control and experimental treatments.
Solid Lipid Nanoparticles. Noninvasive, transcorneal treatment of mouse
retina was achieved with the use of SLNs, patented by Nanovector srl (SI
Methods) (40). The concentration of myriocin in SLN preparations was de-
termined by extraction with chloroform:methanol:37% HCl (100:200:1 by
volume) followed by TLC on silica gel plates in l-butanol:acetic acid:water
(3:1:1 by volume). Known amounts of myriocin were loaded on the same TLC
plate to generate a standard curve. Separated lipids were visualized by
staining with an aqueous solution of 10% CuSO4, 8% H3PO2 on a hot plate
(180 °C) for 3–6 min. Myriocin spots were quantiﬁed by densitometry (Gel
Doc 2000 and Quantity One software; Bio-Rad).
Topical Administration of SLNs. To determine whether lipophilic molecules
contained in SLNs penetrate the inner eye, wild-type mice were treated three
times per day with 1 μL SLNs labeled with coumarin, Nile red, or NBD-DPPE;
unlabeled SLNs served as control. After 3 d of treatment, vertical retina
sections were examined by ﬂuorescence confocal microscopy for the pres-
ence and localization of the ﬂuorophore within the retina. To determine
whether the observed ﬂuorescence corresponded to the ﬂuorophore ad-
ministered topically, the emission spectrum from retinal sections was com-
pared with that of a smear of the SLNs on a microscope slide by ﬂuorescent
spectral analysis using the confocal microscope’s 488-nm laser source. For
pharmacological treatment, rd10 mice (66 animals from 10 litters) and wild-
type mice (n = 12) were administered once daily with either myriocin-SLNs or
control SLNs in both eyes. Each treatment consisted of a double dosage,
within a 15-min interval, of 750–1,000 nL/eye (larger volumes were used in
older animals). Treatment started on P14 (eye opening) and continued until
analysis between P21 and P35.
Fluorescence Microscopy on Retinal Vertical Sections. Retinas from rd10 and
wild-type mice that had been treated with SLNs were harvested for mor-
phological analysis. Photoreceptor survival was assessed by counting nuclei in
the ONL. Photoreceptor morphology was assessed by immunohistochemistry
(SI Methods).
Statistical Analysis. Data were compared by two-tailed unpaired or paired t
tests or with the Wilcoxon–Mann–Whitney test when the distribution of
data was not normal, as assessed by analysis with SigmaStat v. 3.1 (Systat).
Statistical analysis was performed with Origin v. 7.0 (OriginLab) and Sig-
maStat v. 3.1 software packages for Windows XP. A P value <0.05 was
considered signiﬁcant.
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